Is there room for immunomodulators in ulcerative colitis?

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017 Apr 29;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018 Mar;16(3):343–356 e3.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431–440.
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012 Dec;107(12):1879–1887.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012 Aug;107(8):1228–1235.
   PubMed Web of Science ®Google Scholar
• Parragi L, Fournier N, Zeitz J, et al. Colectomy rates in ulcerative colitis are low and decreasing: 10-year follow-up data from the Swiss IBD cohort study. J Crohns Colitis. 2018 Jun 28;12(7):811–818.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015 Sep;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Battat R, Duijvestein M, Guizzetti L, et al. Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. Am J Gastroenterol. 2019 May;114(5):733–745.
   PubMed Web of Science ®Google Scholar
• Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016 Mar;65(3):408–414.
   PubMed Web of Science ®Google Scholar
• Choi CR, Al Bakir I, Ding NJ, et al. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut. 2019;68(3):414–422.
   Google Scholar
• Pai RK, Jairath V, Vande Casteele N, et al. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointest Endosc. 2018 Dec;88(6):887–898.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257–65e1–3.
   Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96–109 e1.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):85–95; quiz e14–5.
   Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Danese S, Sands BE, O’Brien CD, et al. Efficacy and safety of ustekinumab through week 16 in patients with moderate to severe ulcerative colitis randomized to ustekinumab: results from the unifi induction trial. Gastroenterology. 2019;156(6):S–1106.
   Web of Science ®Google Scholar
• Sandborn WJ, Sands BE, Panaccione R, et al. OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: week 44 results from UNIFI. J Crohn’s Colitis. 2019;13(Supplement_1):S025–S026.
   Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 May 4;376(18):1723–1736.
   PubMed Web of Science ®Google Scholar
• Wang Y, Parker CE, Bhanji T, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016 Apr;21(4):CD000543.
   Google Scholar
• Wang Y, Parker CE, Feagan BG, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016 May;9(5):CD000544.
   Google Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012 Nov;14(11):CD004118.
   Google Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010 Jan;20(1):CD004115.
   Google Scholar
• Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust. 1962 Oct 13;49(2):592–593.
   PubMed Web of Science ®Google Scholar
• Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753–767.
   PubMed Web of Science ®Google Scholar
• Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996 Aug 23;273(5278):1109–1111.
   PubMed Web of Science ®Google Scholar
• Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003 Apr;111(8):1133–1145.
   PubMed Web of Science ®Google Scholar
• Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005 Feb;312(2):537–545.
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 Sep;32(5):651–662.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009 Feb;104(2):465–83;quiz 464, 484.
   PubMed Web of Science ®Google Scholar
• Warner B, Johnston E, Arenas-Hernandez M, et al. A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterol. 2018 Jan;9(1):10–15.
   PubMed Web of Science ®Google Scholar
• Gilissen LP, Wong DR, Engels LG, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis. 2012 Jul;6(6):698–707.
   PubMed Web of Science ®Google Scholar
• van Asseldonk DP, Sanderson J, de Boer NK, et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease–proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis. 2011 Apr;43(4):270–276.
   PubMedGoogle Scholar
• Reinshagen M, Schutz E, Armstrong VW, et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem. 2007 Jul;53(7):1306–1314.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Nguyen GC, Kupfer SS, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017 Sep;153(3):827–834.
   PubMed Web of Science ®Google Scholar
• Malaviya AN. Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story. Int J Rheum Dis. 2016 Sep;19(9):844–851.
   PubMed Web of Science ®Google Scholar
• Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc. 1996 Jan;71(1):69–80.
   PubMed Web of Science ®Google Scholar
• Brody M, Bohm I, Bauer R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem. 1993 Oct;31(10):667–674.
   PubMedGoogle Scholar
• Sperling RI, Benincaso AI, Anderson RJ, et al. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheumatism. 1992 Apr;35(4):376–384.
   PubMedGoogle Scholar
• Cronstein BN, Eberle MA, Gruber HE, et al. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2441–2445.
   PubMed Web of Science ®Google Scholar
• Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003 Jul 1;18(1):57–63.
   PubMed Web of Science ®Google Scholar
• Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013 Dec;72(12):1947–1955.
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002 Apr;50(4):485–489.
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Sood N, et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol. 2000 Jan–Mar;19(1):14–16.
   PubMedGoogle Scholar
• Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol. 1997 Jul;25(1):330–333.
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Baker JP, Brzezinski A, et al. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol. 1990 Jun;12(3):271–275.
   PubMed Web of Science ®Google Scholar
• Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990 Jun;85(6):717–722.
   PubMed Web of Science ®Google Scholar
• Lobo AJ, Foster PN, Burke DA, et al. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum. 1990 May;33(5):374–377.
   PubMed Web of Science ®Google Scholar
• Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J. 1974 Dec 14;4(5945):627–630.
   PubMed Web of Science ®Google Scholar
• Bowen GE, Irons GV Jr., Rhodes JB, et al. Early experiences with azathioprine in ulcerative colitis; a note of caution. JAMA. 1966 Feb 7;195(6):460–464.
   PubMed Web of Science ®Google Scholar
• Sood R, Ansari S, Clark T, et al. Long-term efficacy and safety of azathioprine in ulcerative colitis. J Crohns Colitis. 2015 Feb;9(2):191–197.
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Sood N, et al. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol. 2006 Dec 7;12(45):7332–7336.
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004 Jun;99(6):1122–1128.
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Sood N, et al. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003 May–Jun;22(3):79–81.
   PubMedGoogle Scholar
• Sood A, Kaushal V, Midha V, et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol. 2002;37(4):270–274.
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992 Jul 4;305(6844):20–22.
   PubMed Web of Science ®Google Scholar
• Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology. 1975 Jul;69(1):96–99.
   PubMed Web of Science ®Google Scholar
• Caprilli R, Carratu R, Babbini M. Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. Am J Dig Dis. 1975 Feb;20(2):115–120.
   PubMedGoogle Scholar
• Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol. 2000 May;95(5):1201–1207.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006 Jan;55(1):47–53.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009 Jul 1;30(2):126–137.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Nino P, Cara C, et al. Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther. 2008 Jul;28(2):228–238.
   PubMed Web of Science ®Google Scholar
• Glazier KD, Palance AL, Griffel LH, et al. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2005 Jan;39(1):21–26.
   PubMed Web of Science ®Google Scholar
• Lopez- Sanroman A, Bermejo F, Carrera E, et al. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther. 2004 Jul 15;20(2):161–166.
   PubMed Web of Science ®Google Scholar
• Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol. 2004 Mar;99(3):462–465.
   PubMed Web of Science ®Google Scholar
• Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38(8):740–746.
   PubMed Web of Science ®Google Scholar
• Christodoulou D, Katsanos K, Baltayannis G, et al. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece. Hepatogastroenterology. 2003 Jul–Aug;50(52):1021–1024.
   PubMedGoogle Scholar
• Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001 May;48(5):642–646.
   PubMed Web of Science ®Google Scholar
• Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther. 2002 Oct;16(10):1751–1759.
   PubMed Web of Science ®Google Scholar
• Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol. 2001 Nov;13(11):1297–1301.
   PubMed Web of Science ®Google Scholar
• Pugliese D, Aratari A, Festa S, et al. Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: a real-life study. Gastroenterol Res Pract. 2018;2018:4195968.
   PubMedGoogle Scholar
• Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016 May;18(5):CD000478.
   Google Scholar
• Eriksson C, Rundquist S, Cao Y, et al. Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut. 2019 Apr;68(4):623–632.
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol. 2009 Nov;104(11):2760–2767.
   PubMed Web of Science ®Google Scholar
• Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996 May;110(5):1416–1421.
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625–1629.
   PubMed Web of Science ®Google Scholar
• Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Nov;12(11):1227–1233.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995 Feb 2;332(5):292–297.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000 Jun 1;342(22):1627–1632.
   PubMed Web of Science ®Google Scholar
• Herfarth HH, Kappelman MD, Long MD, et al. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2016 Jan;22(1):224–233.
   PubMed Web of Science ®Google Scholar
• Khan N, Abbas AM, Moehlen M, et al. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the veterans affairs health care system. Inflamm Bowel Dis. 2013 Jun;19(7):1379–1383.
   PubMed Web of Science ®Google Scholar
• Herfarth HH, Osterman MT, Isaacs KL, et al. Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis. 2010 Aug;16(8):1421–1430.
   PubMed Web of Science ®Google Scholar
• Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2009 Sep 15;30(6):614–620.
   PubMed Web of Science ®Google Scholar
• Cummings JR, Herrlinger KR, Travis SP, et al. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther. 2005 Feb 15;21(4):385–389.
   PubMed Web of Science ®Google Scholar
• Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther. 2002 Apr;16(4):693–697.
   PubMed Web of Science ®Google Scholar
• Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci. 1993 Oct;38(10):1851–1856.
   PubMed Web of Science ®Google Scholar
• Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989 Mar 1;110(5):353–356.
   PubMed Web of Science ®Google Scholar
• Carbonnel F, Colombel JF, Filippi J, et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016 Feb;150(2):380–8 e4.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Renna S, Cottone M, et al. The METEOR trial: the burial of methotrexate in ulcerative colitis? Gastroenterology. 2016 Jul;151(1):211–212.
   PubMed Web of Science ®Google Scholar
• Herfarth H, Barnes EL, Valentine JF, et al. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology. 2018 Oct;155(4):1098–1108 e9.
   PubMed Web of Science ®Google Scholar
• Wang Y, MacDonald JK, Vandermeer B, et al. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015 Aug;11(8):CD007560.
   Google Scholar
• Chande N, Wang Y, MacDonald JK, et al. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014 Aug;27(8):CD006618.
   Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014 Feb;146(2):392–400 e3.
   PubMed Web of Science ®Google Scholar
• Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013 Jun;168(6):1325–1334.
   PubMed Web of Science ®Google Scholar
• Lee YY, Gangireddy V, Khurana S, et al. Are we ready for combination therapy in moderate-to-severe ulcerative colitis? Gastroenterology. 2014 Aug;147(2):544.
   PubMed Web of Science ®Google Scholar
• Kamath N, Kamath A, Pai CG. Infliximab for moderate to severe ulcerative colitis: the jury isn’t in yet. Gastroenterology. 2014 Aug;147(2):544–545.
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014 Mar;146(3):681–688 e1.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Orlando A. Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective? Minerva Gastroenterol Dietol. 2019 Oct 9. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Apr;11(4):444–447.
   PubMed Web of Science ®Google Scholar
• Ong DE, Kamm MA, Hartono JL, et al. Addition of thiopurines can recapture response in patients with Crohn’s disease who have lost response to anti-tumor necrosis factor monotherapy. J Gastroenterol Hepatol. 2013 Oct;28(10):1595–1599.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Karatzas P, Mantzaris GJ. Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn’s disease. J Crohns Colitis. 2015 Jul;9(7):589–590.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Sapienza C, Ventimiglia M, et al. The addition of an immunosuppressant after loss of response to anti-TNFalpha monotherapy in inflammatory bowel disease: a 2-year study. Inflamm Bowel Dis. 2018 Jan 18;24(2):394–401.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Renna S, Maida M, et al. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Scand J Gastroenterol. 2017 Sep;52(9):981–987.
   PubMed Web of Science ®Google Scholar
• Cohn HM, Dave M, Loftus EV Jr. Understanding the cautions and contraindications of immunomodulator and biologic therapies for use in inflammatory bowel disease. Inflamm Bowel Dis. 2017 Aug;23(8):1301–1315.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013 Jun;19(7):1404–1410.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Rhatigan E, Arnott ID, et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther. 2013 Nov;38(10):1255–1266.
   PubMed Web of Science ®Google Scholar
• Rosen DJ, Dubinsky MC. The evolving role of thiopurines for inflammatory bowel disease. Inflamm Bowel Dis. 2016 Jan;22(1):234–240.
   PubMed Web of Science ®Google Scholar
• Moon W, Loftus EV Jr. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2016 Apr;43(8):863–883.
   PubMed Web of Science ®Google Scholar
• Wilson A, Jansen LE, Rose RV, et al. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Mar;47(5):615–620.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Vacek PM, O’Neill P, et al. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res. 2009 Sep 1;69(17):7004–7012.
   PubMed Web of Science ®Google Scholar
• Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012 Aug;143(2):390–399 e1.
   PubMed Web of Science ®Google Scholar
• Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 2015 May;21(5):1089–1097.
   PubMed Web of Science ®Google Scholar
• Pasternak B, Svanstrom H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013 Jun 1;177(11):1296–1305.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015 May;13(5):847–58e4; quiz e48–50.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009 Nov 7;374(9701):1617–1625.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011 Jan;9(1):36–41 e1.
   PubMed Web of Science ®Google Scholar
• Lam GY, Halloran BP, Peters AC, et al. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: lessons from other inflammatory disorders. World J Gastrointest Pathophysiol. 2015 Nov 15;6(4):181–192.
   PubMedGoogle Scholar
• Subramaniam K, Cherian M, Jain S, et al. Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications. Intern Med J. 2013 Dec;43(12):1339–1342.
   PubMed Web of Science ®Google Scholar
• Salado CT, Gallego AG, Carnerero EL, et al. Hemophagocytic lymphohistiocytosis in Crohn’s disease associated with primary infection by Epstein-Barr virus. Inflamm Bowel Dis. 2011 Nov;17(11):E143–4.
   PubMed Web of Science ®Google Scholar
• Biank VF, Sheth MK, Talano J, et al. Association of Crohn’s disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr. 2011 Nov;159(5):808–812.
   PubMed Web of Science ®Google Scholar
• de Francisco R, Castano-Garcia A, Martinez-Gonzalez S, et al. Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Oct;48(7):723–730.
   PubMed Web of Science ®Google Scholar
• Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am. 1994 May;20(2):513–528.
   PubMed Web of Science ®Google Scholar
• Parker R, Dixit A, Fraser A, et al. Clinical experience of methotrexate in Crohn’s disease: response, safety and monitoring of treatment. Postgrad Med J. 2010 Apr;86(1014):208–211.
   PubMed Web of Science ®Google Scholar
• Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994 Dec 1;121(11):833–841.
   PubMed Web of Science ®Google Scholar
• Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993 Jun;36(6):795–803.
   PubMed Web of Science ®Google Scholar
• Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May;31(5):CD000951.
   Google Scholar
• Gabbani T, Deiana S, Lunardi S, et al. Safety profile of methotrexate in inflammatory bowel disease. Expert Opin Drug Saf. 2016 Oct;15(10):1427–1437.
   PubMed Web of Science ®Google Scholar
• Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000 Nov;23(5):429–448.
   PubMed Web of Science ®Google Scholar
• Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000 Nov;95(11):3150–3156.
   PubMed Web of Science ®Google Scholar
• Fournier MR, Klein J, Minuk GY, et al. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010 Jul;105(7):1620–1626.
   PubMed Web of Science ®Google Scholar
• Valentino PL, Church PC, Shah PS, et al. Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014 Jan;20(1):47–59.
   PubMed Web of Science ®Google Scholar
• Khan N, Abbas AM, Whang N, et al. Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012 Feb;18(2):359–367.
   PubMed Web of Science ®Google Scholar
• Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl). 2018;8:21–29.
   PubMed Web of Science ®Google Scholar
• Margagnoni G, Papi V, Aratari A, et al. Methotrexate-induced pneumonitis in a patient with Crohn’s disease. J Crohns Colitis. 2010 Jun;4(2):211–214.
   PubMed Web of Science ®Google Scholar
• D’Andrea N, Triolo L, Margagnoni G, et al. Methotrexate-induced pneumonitis in Crohn’s disease. Case report and review of the literature. Multidiscip Respir Med. 2010 Oct 31;5(5):312–319.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016 Mar;150(3):734–757 e1.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving considerations for thiopurine therapy for inflammatory bowel diseases-a clinical practice update: commentary. Gastroenterology. 2019 Jan;156(1):36–42.
   PubMed Web of Science ®Google Scholar
• Ma C, Panaccione R, Fedorak RN, et al. Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set. Clin Gastroenterol Hepatol. 2018 May;16(5):637–647 e13.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar;114(3):384–413.
   PubMed Web of Science ®Google Scholar
• Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015 May;148(5):1035–1058 e3.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017 Jul 1;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014 Mar;63(3):433–441.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov;143(5):1218–1226 e2.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Adedokun OJ, Gasink C, et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1525–1532 e1.
   PubMed Web of Science ®Google Scholar
• Cheifetz A. Overview of therapeutic drug monitoring of biologic agents in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2017 Sep;13(9):556–559.
   Google Scholar
• Hedin C, Halfvarson J. Should we use vedolizumab as mono or combo therapy in ulcerative colitis? Best Pract Res Clin Gastroenterol. 2018 Feb–Apr;32–33: 27–34.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: 3 year efficacy, safety, and immunogenicity of Ustekinumab treatment of Crohn’s disease. J Crohns Colitis. 2020Jan;14(1):23–32.
   Google Scholar
• Pagnini C, Pizarro TT, Cominelli F. Novel pharmacological therapy in inflammatory bowel diseases: beyond anti-tumor necrosis factor. Front Pharmacol. 2019;10:671.
   PubMed Web of Science ®Google Scholar
• Katsanos KH, Papamichael K, Feuerstein JD, et al. Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies. Clin Immunol. 2019;206:9–14.
   PubMed Web of Science ®Google Scholar
• Battat R, Ma C, Jairath V, et al. Benefit-risk assessment of vedolizumab in the treatment of Crohn’s disease and ulcerative colitis. Drug Saf. 2019 May;42(5):617–632.
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015 Jul;14(7):706–714.
   PubMed Web of Science ®Google Scholar
• Naeem M, Bae J, Oshi MA, et al. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit((R)) FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomedicine. 2018;13:1225–1240.
   PubMed Web of Science ®Google Scholar
• Beattie DT, Pulido-Rios MT, Shen F, et al. Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy. J Inflamm (Lond). 2017;14:28.
   PubMed Web of Science ®Google Scholar